INCY Incytedata gap · 92% coverage
Health Care · Biotechnology · close $113.07 (2026-10-16) · latest quarter in EDGAR: 2026-03-31
Incyte (INCY) has a ThetaGrade House Rating of 65/100 (grade B), ranking #60 of 150 in Health Care. Its strongest pillars are cash flow (88) and growth (72); its weakest is balance sheet (40). Data gap: 2 factors without usable data, so 92% of the method weight is covered. TTM revenue growth is 21.5% and operating margin 30.0%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 92% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 72| Revenue growth YoY (TTM) (13.3%) | 21.5% | 74 |
| EPS growth YoY (TTM) (13.3%) | 3440.0% | 99 |
| Revenue acceleration (6.7%) | -7.0% | 14 |
Profitability
weight 18.5% (→20.0%) · 65| Operating margin (10.7%) | 30.0% | 88 |
| 4Q gross-margin change (9.3%) | -0.2% | 38 |
Balance sheet
weight 18.5% (→20.0%) · 40| Net debt / EBITDA (10.7%) | 9.58× | 5 |
| Current ratio (5.3%) | 3.68 | 66 |
| Interest coverage (4.0%) | 663.43× | 99 |
Cash flow
weight 12.33% (→13.3%) · 88| FCF margin (6.7%) | 26.3% | 87 |
| FCF yield (6.7%) | 6.0% | 89 |
Valuation
weight 12.33% (→13.3%) · 64| P/E (inverted) (6.7%) | 15.97× | 89 |
| EV/Sales (inverted) (6.7%) | 7.26× | 38 |
Technicals (EOD)
| RSI(14) | 39.4 |
| EMA 9 / 21 | 113.17 / 116.35 |
| 200-day SMA | 107.50 |
| Volume vs 20d avg | 0.86× |
| 20-day return | -11.4% |
Exit-rule monitor
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfRevenue · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like INCY's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is INCY's House Rating?
- INCY scores 65 out of 100 (grade B) as of 2026-10-16, ranking #60 of 150 Health Care stocks we cover.
- What do analysts say about INCY?
- We do not have enough analyst-sentiment data to score this stock.
- When does INCY report earnings next?
- INCY's next earnings report is estimated for about 2026-10-27 (window 2026-10-24 to 2026-10-30), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is INCY a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology